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2Abstract
Objective Cannabidiol (CBD) and delta-9-tetrahydrocannabivarin (THCV) are non-
psychoactive phytocannabinoids affecting lipid and glucose metabolism in animal 
models. This study set out to examine the effects of these compounds in patients with 
type 2 diabetes.
Research Design and Methods In this randomised, double-blind, placebo-controlled 
study, 62 subjects with non-insulin treated type 2 diabetes were randomised to five 
treatment arms; CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD 
and THCV (5 mg:5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg:5 mg, twice 
daily), or matched placebo, for 13 weeks. The primary endpoint was a change in HDL-
cholesterol concentrations from baseline. Secondary/tertiary endpoints included 
changes in glycaemic control, lipid profile, insulin sensitivity, body weight, liver 
triglyceride content, adipose tissue distribution, appetite, markers of inflammation, 
markers of vascular function, gut hormones, circulating endocannabinoids and 
adipokine concentrations. Safety and tolerability endpoints were also evaluated.
Results Compared with placebo, THCV significantly decreased fasting plasma 
glucose (estimated treatment difference (ETD)=-1.2mmol/L, P<0.05) and improved 
pancreatic β-cell function (homeostasis model assessment (HOMA2 B) (ETD=-44.51 
points, P<0.01), adiponectin (ETD=-5.9 x 106pg/mL, P<0.01) and apolipoprotein A 
(apoA) (ETD=-6.02µmol/L, P<0.05), although plasma HDL was unaffected. Compared 
to baseline (but not placebo), CBD decreased resistin (-898 pg/ml, P<0.05) and 
increased glucose-dependent insulinotropic peptide (21.9 pg/ml, P<0.05). None of the 
combination treatments had a significant impact on endpoints. CBD and THCV were 
well tolerated.
3Conclusions THCV could represent a new therapeutic agent in glycaemic 
control in subjects with type 2 diabetes. 
The endocannabinoid system (ECS) modulates food intake and energy homeostasis 
(1, 2) and chronic over-activation of the ECS has been identified in obesity and type 
2 diabetes (3). The ECS exerts some of its actions by various components activating 
cannabinoid receptors 1 (CB1) and 2 (CB2). Modulation of CB1 receptors with 
rimonabant (a synthetic cannabinoid) led to a significant reduction in body weight, 
waist circumference and triglyceride (TG) concentrations, and an increase in HDL-
cholesterol and adiponectin concentrations (4), as well as a reduction in HbA1c in 
subjects with type 2 diabetes (- 0.8% to – 1.25%, P<0.001). However, marketing 
authorisation for rimonabant was withdrawn in 2008 because of an increased 
incidence of psychiatric adverse events (AEs) (5). Rimonabant is thought to be a 
CB1 receptor antagonist/inverse agonist, but it is unclear whether modulation of other 
cannabinoid receptor activity could have beneficial metabolic effects without 
significant psychiatric effects.
Cannabidiol (CBD) is one of the major phytocannabinoids obtained from the 
Cannabis sativa L. plant. In rodent studies, CBD has multiple desirable effects in the 
context of hyperglycaemia, mainly through its anti-inflammatory and anti-oxidant 
properties (6-10). In animal models of obesity (ob/ob genetically obese mice), four 
weeks treatment with CBD 3mg/kg, produced a 55% increase in HDL-C 
concentration and reduced total cholesterol (total-C) by more than 25% (GW Pharma 
data on file). In addition, the same dose reduced liver triglycerides and increased 
both liver glycogen and adiponectin concentration. There is also evidence from 
animal studies showing that CBD modulates cardiovascular response to stress (11).
Unlike the related molecule ∆9-tetrahydrocannabinol (THC), CBD does not activate 
CB1 receptors in the brain and therefore lacks the psychotropic actions of THC.  
Indeed, CBD may reduce psychosis (12) and mitigate the psychoses associated with 
cannabis misuse (13). Other receptor sites implicated in the actions of CBD include 
the orphan G-protein coupled receptor-55 (GPR55), the putative endothelial 
cannabinoid receptor (CBe), the transient receptor potential vanilloid 1 (TRPV1) 
receptor, α1-adrenoceptors, µ opioid receptors, the adenosine transporter and 
serotonin-1A (5-HT1A) receptors (14). CBD also activates and has physiological 
responses mediated by peroxisome proliferator activated receptor γ (PPARγ) (15,16, 
17). A CBD/THC combination (Sativex®/Nabiximols) is currently licensed in most EU 
countries and in Canada, New Zealand, Australia, Malaysia, the United Arab 
Emirates and Kuwait, for the symptomatic treatment of spasticity in moderate to 
severe multiple sclerosis, and CBD alone (Epidiolex®) was granted orphan drug 
designation by the FDA in February 2014 in Dravet and Lennox-Gastaut syndromes 
in children, with Phase 3 clinical trials ongoing in those conditions.
Δ9-tetrahydrocannabivarin (THCV) is a naturally occurring analogue of THC, but with 
different pharmacological effects. It is has been reported to behave as both a 
CB1/CB2 agonist and/or a CB1/CB2 neutral antagonist (20, 21, 22, 23,24), probably 
dose-dependent, with agonism observed at high doses and antagonism at low doses 
(21). However, there is little evidence of CB1 agonsim in vivo compared with the 
observed in vivo effects of THC at similar doses. Other target sites of action include 
GPR55 (25) and transient receptor potential channels (26, 27).
Acute intraperitoneal administration of THCV in rodents at 3, 10 and 30 mg/kg body 
weight, caused hypophagia and weight loss, with food intake and body weight 
returning to normal on day 2 (18). The effect was similar to that of a CB1 antagonist 
AM251, also used in the same study. In another study, involving diet-induced obese 
(DIO) mice, oral THCV (2.5 to 12.5 mg/kg) reduced body fat content, increased 
energy expenditure, and reduced fasting insulin and 30 min insulin response to oral 
glucose tolerance test (OGTT) (19). In the same study, in genetically obese (ob/ob) 
mice, a similar increase in 24-hour energy expenditure was observed with 3mg/kg 
THCV, while 12.5 mg/kg THCV caused a significant reduction in liver triglycerides 
(19). In genetically obese mice (ob/ob), a 1:1 ratio of a combination of THCV and 
CBD (3 mg/kg:3 mg/kg) reduced total cholesterol levels by 19% and increased HDL-
C by 50%. The same combination reduced liver TG, increased liver glycogen levels, 
reduced fasting insulin and increased energy expenditure (GW Pharma data on file).
The findings from these preclinical studies demonstrate a potential beneficial effect 
of both CBD and THCV, alone or in combination, in diabetes and lipid metabolism, 
with very distinct pharmacological profiles, and therefore different side effects, to 
rimonabant. This prompted the first ever investigation of the effects of CBD and 
THCV on dyslipidaemia and glycaemic control in subjects with type 2 diabetes.
Research Design and Methods 
Subjects and study design
This randomised, double-blind, placebo-controlled, parallel-group, phase 2a proof-of-
concept study was conducted at four United Kingdom centres. The protocol was 
reviewed and approved by the East Midlands - Leicester Multi Centre Research 
Ethics Committee (10/H0406/42) and local R&D departments as required, and was 
conducted in accordance with the Declaration of Helsinki. All subjects provided 
written informed consent.
Subjects aged 18 years or above with type 2 diabetes and HbA1c ≤10% 
(86 mmol/mol), HDL-C ≤1.3mmol/L in females and ≤1.2mmol/L in males, and plasma 
triglycerides ≤10mmol/L, were eligible. Subjects needed to either receive no oral 
hypoglycaemic agents or take stable doses of pre-specified non-insulin glucose 
lowering therapies (metformin, sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitor 
or glucagon-like peptide-1 (GLP-1) therapy) for three months prior to screening. 
Subjects not on statin therapy or on a stable dose of a statin, for at least four weeks 
prior to randomisation, were eligible for inclusion. Subjects were also required not to 
make any changes to their diet or exercise for four weeks prior to randomisation and 
during the course of the study.
Main exclusion criteria (see supplemental data for full details) included use of 
prohibited medications (insulin, fibrates, thiazolidinediones, therapeutic omega-3 
fatty acids, alpha-glucosidase inhibitors), recent or current use of cannabis, history of 
significant depression, planned travel outside the UK during the course of study, 
genetic dyslipidaemia or significant cardiac, renal or hepatic impairment. 
There was a one to five week period between screening (visit 1) and treatment 
randomisation (visit 2). Visit 1 could be split into two separate visits (1A and B) to 
allow a 21-day washout period of the prohibited medications prior to blood sampling 
for eligibility. Remaining visits occurred 4, 8 and 13 weeks after initiation of treatment 
(visits 3, 4 and 5, respectively), or earlier if patients withdrew.  A safety follow up visit 
occurred 7 days after study completion or withdrawal (visit 6). Visits 4 and 6 were 
telephone assessments. 
Patients were required to take study medication in the fasted state, twice daily, 30 
minutes before breakfast and 30 minutes before evening meal, typically 12 hours 
apart for 13 weeks.
Study endpoints and assessments
The primary endpoint was change in mean serum HDL-C from baseline, in CBD and 
THCV groups, compared with the change in placebo group, at week 13. Secondary 
endpoints included changes in lipid profile, glycaemic control, insulin sensitivity, body 
weight, visceral adiposity, appetite and cardiovascular function. Tertiary endpoints 
were changes in markers of inflammation, vascular function, adipokines, 
endocannabinoids and gut hormone concentrations.
Serum lipid concentrations were analysed with the Roche modular system using 
enzymatic calorimetric assays. Non-esterified fatty acid (NEFA) concentrations were 
quantified on the Roche COBAS 311 system, using an acyl-CoA synthetase/acyl-
CoA oxidase (ACS-ACOD) method. Apolipoprotein markers were analysed on the 
Roche COBAS 311 system, using immunoturbidimetric assays, based on the 
principle of immunological agglutination. Plasma VLDL-C concentrations were 
determined by ultracentrifugation.
A standard 75 g OGTT was performed and plasma glucose and serum insulin were 
analysed using the Roche modular system and Advia Centaur immunoassay 
analyser respectively. HOMA-insulin resistance (IR), insulin sensitivity and β-cell 
function were calculated using the HOMA2 Calculator v2.2© (Diabetes Trials Unit, 
University of Oxford).
Plasma endocannabinoids, N-arachidonoylethanolamine (AEA), 2-
arachidonoylglycerol (2-AG), oleoylethanolamine (OEA) and palmitoylethanolamine 
(PEA), were analysed using liquid chromatography-tandem mass spectrometry, 
based on a previously published method (28). Ketones, orexin A and retinol binding 
protein (RBP) 4 were analysed using immunoassay, while all other tertiary endpoints 
including adiponectin, resistin, leptin, E-Selectin, vascular cell adhesion molecule 
(VCAM), Von Willebrand factor (vWF), C-reactive protein (CRP), interleukin (IL) 6, 
tumour necrosis factor (TNF) α, glucose-dependent insulinotropic peptide (GIP), 
ghrelin and GLP-1 were analysed by multiplex analysis, using commercially available 
kits (Milliplex™, HMHMAG-34K, HCVD1-67AK, HADK-1-61K-A, HCVD2-67BK, 
BPHCVD05-6, Merck Millipore®).
Resting blood pressure was measured using digital blood pressure monitor while 
cardiovascular parameters including systolic, diastolic and mean arterial pressure, 
heart rate, stroke volume, cardiac output, inter beat interval, ejection time and total 
peripheral resistance were measured using a Finometer® (Finapres Medical 
Systems), which uses a finger-clamp method to detect beat-to-beat changes in 
digital arterial diameter with an infrared photoplethysmograph. 
Adipose tissue distribution was assessed using whole body magnetic resonance 
imaging (MRI); images were analysed by a blinded investigator using SliceOmatic™. 
Body weight and 7-point skin fold measures were also recorded. Hepatic TG 
concentration was assessed using magnetic resonance spectroscopy (MRS) and 
analysed using JMRUI software
Subject’s Global Impression of Change (SGIC) and Clinician’s Global Impression of 
Change (CGIC) was assessed using an ordinal 7-point Likert scale (1=very much 
improved to 7=very much worse). Changes in appetite were established using 
patients’ scores of their appetites that they recorded on daily basis using an appetite 
0-10 numerical rating scale (NRS), where 0=no appetite (don’t feel hungry) and 
10=maximum appetite (completely hungry all the time) (29). The change from mean 
baseline score (mean of seven days before start of treatment) was compared to the 
mean score from the last seven days on treatment (end of 13 weeks).
Safety assessments included reporting for adverse events (AEs) and serious 
adverse events (SAEs), recording vital signs, pre- and post-treatment laboratory 
sampling and electrocardiograms (ECG) and change from baseline in Beck 
Depression Inventory-II (BDI-II) scores.
The BDI-II questionnaire, an assessment for anxiety and depression, is a multiple 
choice, self-reported inventory, and is one of the most widely used and validated 
instruments for measuring severity of depression (30).
Statistical methods
An independent statistician produced a schedule for random treatment allocation 
which was held centrally and not divulged to any other person involved in the study 
until the database had been locked. Patients were randomly allocated to treatment 
groups in a 1:1:1 ratio, stratified by centre, according to the randomisation schedule. 
Study site staff identified the pack number to be dispensed to the subject at each of 
Visits 2 and 3 according to the randomisation schedule.
Analysis was performed using the intention-to-treat (ITT) population; all subjects who 
were randomised, received at least one dose of study medication and had on-
treatment efficacy data. All statistical tests were two-sided at the 5% significance 
level. Between group differences and 95% confidence intervals (CI) were also 
calculated. The primary endpoint and the majority of secondary endpoints were 
analysed using analysis of covariance (ANCOVA) of the changes from baseline to 
the end of treatment in the associated parameter, with the exception of the SGIC and 
CGIC, which were analysed with ordinal logistic regression using the cumulative 
proportional odds model. The parameter’s baseline values were included as a 
covariate, and treatment was included as a factor. The tertiary variables were 
analysed using ANCOVA with baseline value as covariate and treatment group and 
gender as factors, or using pairwise Fisher’s Exact test, as appropriate. The null 
hypothesis was one of no difference in the effects of any of the active treatments 
compared individually with placebo. As this study was a phase 2a proof of concept 
study, no formal sample size calculation was performed.
Changes from baseline in all the plasma markers were analysed post hoc using a 
paired t-test, and the glucose response to OGTT was analysed using repeated 
measures 2-way ANOVA.
Results
One hundred and twenty-five patients were screened and 62 randomised to the five 
treatment arms. . The disposition of subjects enrolled is presented in Figure 1. 
Subjects were similar between treatment groups (Table 1) in terms of baseline 
characteristics.
Lipids 
THCV had no effect on HDL-C concentrations (Table 2), but it increased Apo A 
concentrations compared with placebo from baseline to the end of treatment (from 
48.5 to 49.1 µmol/L in the THCV vs. 47.3 to 43.9 µmol/L in the placebo group; 
P<0.05, Fig. 2A). THCV had no effect on LDL-C concentrations. CBD alone and in 
combination with THCV, did not affect any of the lipid parameters (Table 2).
Glycaemic Control
THCV reduced fasting plasma glucose concentration compared with placebo from 
baseline to the end of treatment (from 7.4 to 6.7 mmol/L in the THCV vs. 7.6 to 
8.0 mmol/L in the placebo group, ETD = -1.24 ± 0.6 (SEM), P<0.05, Fig. 3A). In line 
with this, there was a significant increase in HOMA2 B in the THCV treatment group 
compared with placebo from baseline to the end of treatment (from 105.1 to 144.4 in 
the THCV group vs. 96.4 to 94.7 in the placebo group, ETD = 44.6 ± 16.1 (SEM), 
P<0.01, Table 2, Fig 3B). There was no significant difference in glucose response to 
OGTT at 2 hours. However, when compared with baseline, THCV significantly 
improved 3-hour blood glucose response (P<0.05, Fig 3C). CBD alone or in 
combination with THCV had no effect on glycaemic parameters (Table 2).
Vascular Function
Compared to placebo, CBD and THCV, alone and in combination, had no effect on 
cardiovascular parameters (Table 2), or plasma markers of vascular function 
(Supplementary data Table 1).
Adipokines
There was an increase from baseline in adiponectin concentration in the THCV 
group and a reduction in placebo group; the treatment difference was statistically 
significant in favour of THCV treatment (ETD  -5.9 x 106
 
pg/mL, P<0.01, Fig. 3B). 
Plasma concentrations of leptin and resistin remained unchanged with THCV 
treatment. Compared with baseline rather than placebo, CBD caused a significant 
reduction in the concentration of resistin (-898 pg/mL, P<0.05, Fig. 3C), but had no 
effect on leptin or adiponectin. Subjects taking a combination of CBD and THCV had 
no change in adipokine levels (Supplementary data Table 1).
Markers of Inflammation
Both THCV and CBD, or their combination, had no significant effect on plasma 
markers of inflammation (CRP, TNF α and IL-6; supplementary data Table 1).
Gut Hormones
THCV, on its own and in combination with CBD, had no effect on the concentrations 
of gut signalling hormones including GLP-1, GIP and ghrelin (supplementary data 
Table 1). However, in a post-hoc analysis, for which post-treatment concentrations 
were compared with baseline (rather than placebo), CBD caused a significant 
increase in the concentration of GIP (21.2 pg/mL, P<0.05, Fig. 3D), without any 
effect on GLP-1 or ghrelin concentrations.
Body weight 
Baseline mean body weight (kg ± SD) in the CBD, THCV, 1:1 CBD:THCV, 20:1 
CBD:THCV and placebo groups were 97.1 ± 13.8, 98.3 ± 17.5, 100.7 ± 14.5, 100.5 ± 
17.9 and 94.2 ± 19.1 respectively. There were no statistically significant changes in 
anthropometric parameters including weight, waist circumference, waist to hip ratio 
and skin fold thickness in any of the treatment groups (Table 2). 
Visceral adiposity and liver triglycerides
There were no changes in visceral adiposity or liver TG (Table 2) as assessed by 
MRI/MRS in any of the treatment groups.
Appetite
None of the treatments had any significant impact on appetite as assessed by 0-10 
NRS scores (Table 2).
PGIC and CGIC
A full summary of the PGIC and CGIC assessment responses is presented in 
Supplemental Figures 1 and 2. Analysis of these responses showed a treatment 
difference in favour of all the active treatments, to varying degrees, but most notably 
between the 1:1 CBD:THCV and placebo treatment groups on CGIC. There were 
reported improvements in seven out of 11 (63.6%) patients in the CGIC on 1:1 
CBD:THCV treatment, compared with only two of the 14 (14.3%) placebo patients, 
with a recorded improvement on CGIG. This translated to a statistically significant 
treatment effect of 1:1 CBD:THCV treatment compared with placebo, with an odds 
ratio of 9.529 (P<0.05) in the CGIC. No other statistically significant effects were 
calculated for any other active treatment in either assessment. 
Endocannabinoids
There was no significant change in the levels of circulating AEA, 2-AG, OEA and 
PEA after 13 weeks of any treatment (Table 2).
Post hoc analysis in THCV group analysing glucose response t
o OGTT and changes in HbA1c
An improvement in glucose response to OGTT was noted in the THCV group at 3 h 
(see Fig 3C). When subjects on any form of diabetes treatment other than 
diet/metformin were excluded from analysis, this effect became more pronounced 
(P<0.05 at 1 h and P<0.01 at 3 h; n=6, Fig 3D). In the same group of diet/metformin 
only patients, compared with placebo, a significant improvement in HbA1c was also 
observed (P<0.05, Fig 3E). 
Safety
The study medication was well tolerated, with the majority of subjects experiencing 
AEs that were mild or moderate in severity. Treatment-emergent (all causality) AEs 
were reported by 11 of 13 (84.6%) subjects in the CBD group, 11 of 12 (91.7%) in 
the THCV group, 7 of 11 (63.6%) in the 1:1 CBD:THCV group, 8 of 11 (66.7%) in the 
20:1 CBD:THCV group, compared with 13 of 14 subjects (92.9%) receiving placebo. 
The more common treatment-related AE reported by subjects in all the groups, 
except for 20:1 CBD:THCV, was decreased appetite (two subjects (15.4%) receiving 
CBD, four subjects (33.3%) receiving THCV, one subject (9.1%) receiving 1:1 
CBD:THCV and two subjects (14.3%) receiving placebo). None of the subjects in 
20:1 CBD:THCV group experienced an AE of decreased appetite. Two subjects 
reported diarrhoea with THCV, compared to no subjects in the placebo group. Two 
subjects (14.3%) on placebo also reported dizziness. All other treatment-related AEs 
were reported in individual subjects.
No deaths occurred during the study. There were two SAEs in this study. One 
patient (8.3%) taking 20:1 CBD:THCV treatment experienced an SAE of myocardial 
infarction that was considered moderate in severity, had recovered by the end of 
study, and was not considered to be treatment related. One placebo patient 
experienced an SAE of myocardial ischaemia that was not considered to be 
treatment-related, was mild in severity and occurred on Day 92 of the study; the SAE 
was still ongoing at the end of the study.
Mean changes from screening to the end of treatment in BDI-II scores for the CBD, 
THCV and 1:1 CBD:THCV treatment groups were 0.85, 0.58 and 0.27 points, 
respectively, which were not statistically significant from placebo (change from 
baseline of ˗0.08  points), and remained within the ‘minimal depression’ range for all 
treatments. The largest change from baseline to the end of treatment in BDI-II score 
was in the 20:1 CBD:THCV treatment group (4.91 points). While this remained in the 
‘minimal depression’ bracket, it was statistically significant compared to placebo 
(ETD = 4.77, P<0.01).
Conclusions
The aim of this pilot study was to investigate the clinical effect and tolerability of two 
phytocannabinoids, THCV and CBD, alone and in combination, in subjects with type 
2 diabetes and dyslipidaemia. THCV significantly decreased fasting plasma glucose, 
and increased β-cell function, adiponectin and Apo A concentrations, and was well 
tolerated in patients. These findings suggest that THCV may represent a new 
therapeutic agent for glycaemic control in subjects with type 2 diabetes.
The ECS plays an important role in modulating energy intake and expenditure (for 
reviews, see 1, 2), and a chronically over active ECS may have a role in diabetes 
and its various complications (2). A recent cross-sectional study showed that 
marijuana use was associated with lower concentrations of fasting insulin, insulin 
resistance and waist circumference (31). Some of the favourable metabolic effects 
seen with smoking cannabis may be due to partial CB1 agonists like THC, which may 
act as a functional antagonist in conditions of increased endocannabinoid tone like 
obesity, because of its lower CB1 binding affinity and efficiacy in comparison to 2-
AG, whose levels are elevated in visceral obesity
 
(32). Rimonabant, a CB1 receptor 
antagonist, was the first in its class to be used as anti-obesity drug, but led to 
significant psychiatric adverse events (5).  Pre-clinical studies with the plant-derived 
compound THCV have shown that it produces hypophagia and weight reduction in 
lean mice (18) and improves glucose tolerance and insulin sensitivity in DIO mice 
(19). Similar results have been seen with CBD in ob/ob mice (GW Pharma data on 
file) and CBD has been reported to lower the incidence of diabetes in non-obese 
diabetic mice (33), and arrest the onset of autoimmune diabetes in non-obese 
diabetic mice (34). Given the positive metabolic effects of both THCV and CBD in 
preclinical studies and their potent anti-inflammatory and antioxidant properties 
(22,35,36), we decided to investigate, for the first time, their efficacy and tolerability 
in subjects with type 2 diabetes.
THCV Alone
THCV treatment alone had no effect on HDL-C concentration. It did, however, 
produce a significant rise in serum Apo A, when compared with placebo. Apo A 
makes 90% of HDL protein and constitutes an important structural component of the 
HDL particle. Apo A I, which accounts for 70% of the Apo A (the remaining 20% 
accounted for by Apo A II), plays an important role in reverse cholesterol transport 
(37). The significance of this result remains unclear.
THCV significantly reduced fasting blood glucose concentrations, improved HOMA2 
B and improved the 3-hour blood glucose response to OGTT, without any significant 
difference in insulin response. These findings are in keeping with the recent animal 
data, where THCV improved fasting glucose and 30 min glucose response to OGTT, 
and also improved insulin sensitivity by reducing fasting and post glucose insulin 
concentrations (19). In the same study, THCV treatment improved insulin-induced 
phosphorylation of Akt (also known as protein kinase B) in insulin-resistant human 
hepatocytes and mice myotubes, suggesting improved insulin signalling as one of 
the possible mechanisms of action. 
Although there was an improvement in fasting and 3-hour post OGTT blood glucose, 
there were no changes in body weight and gut hormone concentrations. In fact, a 
rise in the concentration of retinol binding protein 4 (RBP-4) was observed with 
THCV, an adipokine that has been associated with obesity and insulin resistance 
(38). Therefore the mechanism by which THCV improves glycaemic control remains 
unclear. 
THCV significantly increased adiponectin concentrations. Adiponectin enhances 
hepatic insulin sensitivity, increases fatty acid oxidation and has important anti-
atherogenic properties. Its concentrations are reduced in obesity and type 2 diabetes 
(39). 
Positive metabolic effects of THCV on glycaemic control and adiponectin 
concentrations were also seen with rimonabant, the first CB1 antagonist to be 
licenced as anti-obesity medication that was later withdrawn from market due to 
increased incidence of psychiatric adverse events (5). It is, however, important to 
emphasize that while rimonabant consistently reduced body weight in all the 
reported randomised clinical trials, no such change was seen with THCV, suggesting 
clear differences in the mechanisms of action of these compounds. Recent animal 
data with THCV similarly showed no effect on body weight (19). Moreover, 
rimonabant improved the lipid profile (increased HDL-C and reduced TG levels), 
while THCV had no effect on lipid parameters in our study (40). There is also a clear 
difference in chemical structure between THCV and rimonabant.  It is therefore 
reasonable to believe that THCV and rimonabant have different pharmacological and 
safety profiles. At micromolar concentrations, THCV inhibits the activity of both fatty 
acid amide hydrolase (FAAH) and monoacyl glycerol lipase (MAGL), thereby 
inhibiting the hydrolysis of AEA and 2-AG respectively (41). THCV, therefore, can act 
as an indirect agonist at the cannabinoid receptors, by enhancing the activity of the 
endocannabinoid system. Since such a change was not seen in our study, it is 
reasonable to believe that, at the dose tested, THCV was unable to modulate the 
endocannabinoid system.  Recent animal data from Wargent and colleagues (19) 
showed that most of the positive metabolic effects of THCV were seen with 5 and 
12.5 mg/kg doses given orally in rodents. In comparison to this, the dose used on 
our study (10 mg/day, approx. 0.1 mg/kg in humans) was much lower.
CBD Alone
Although CBD did not produce any effects on the primary and secondary efficacy 
outcomes compared with placebo, it reduced circulating resistin concentrations from 
baseline, while increasing the concentration of circulating GIP. Increased 
concentrations of resistin are associated with obesity and insulin resistance (42). GIP 
is one of the incretin hormones, produced by K cells in the proximal duodenum, 
which is known to have insulinotropic and pancreatic β-cell preserving properties 
(43). Despite having positive effects on resistin and GIP, CBD did not produce any 
improvement in glycaemic control. 
CBD is known for its indirect agonism at the CB1 receptors, by either increasing CB1 
constitutional activity or the endocannabinoid tone. CBD has been reported to inhibit 
hydrolysis of AEA by FAAH (but only at high  micromolar levels) and also increases 
2-AG levels (39). In a recent clinical study, in subjects with schizophrenia, 800 mg 
per day of CBD treatment significantly increased serum AEA levels and was 
associated with an improvement in clinical profile of these subjects (12). In our study, 
CBD (albeit at a much lower dose), alone or in combination with THCV, had no effect 
on the plasma levels of endocannabinoids, suggesting that it had minimal interaction 
with the endocannabinoid system at the doses investigated.
Studies in rodents have used intraperitoneal CBD in a dose ranging from 
1 mg/kg/day to 20 mg/kg/day, with positive effects on the metabolism seen only with 
higher dose ranges (7, 8, 9). In a 70 kg individual, a 20 mg/kg/day dose equates to 
1400 mg/day. Similarly, human studies have used CBD in higher doses (12, 44). The 
dose used in our study was 200 mg/day, which could possibly explain lack of 
therapeutic effects seen with CBD. 
Combination of CBD and THCV
Except for an improvement in CGIC assessments with 1:1 CBD:THCV treatment, 
none of the efficacy parameters were affected by 1:1 or 20:1 combination of CBD 
and THCV. There was a trend towards an improvement in most lipid parameters and 
the overall incidence of all-causality treatment related AEs was lowest in the 1:1 
CBD:THCV treatment group; these factors could have led to an impression of 
improvement in subjects’ overall condition with this treatment. While the combination 
of CBD and THCV did not produce any favourable effects on any of the parameters, 
the favourable effects of THCV were also lost in the combination treatment. Similarly, 
the positive effects of CBD on GIP and resistin were not seen in any of the 
combination treatments. This suggests that CBD and THCV in combination may 
counteract their individual therapeutic effects at least in the ratios and doses tested 
in this study. This may be at the level of receptors or due to interference with each 
other’s metabolism or therapeutic half-life, and requires further investigation.
Safety
Both CBD and THCV were well tolerated, with the majority of patients experiencing 
AEs that were mild in severity. The most common AE was reduced appetite with 
similar incidence across all the treatment groups. There were no reports of 
depression and no clinically significant abnormalities on ECG and laboratory results 
including blood count, liver and renal biochemistry in any treatment groups. There 
was one SAE of myocardial ischaemia in the placebo group, and one SAE of 
myocardial infarction in the 20:1 CBD:THCV group; both were considered unrelated 
to study medication. With regards to the BDI-II scale, though the change in 20:1 
CBD:THCV treatment group was statistically significant, all mean active treatments 
and placebo scores remained in the ‘minimal depression’ range.
Conclusion
In this clinical study, the first to study the effects of CBD and THCV in subjects with 
type 2 diabetes and dyslipidaemia, THCV improved glycaemic control, and therefore 
warrants further investigation in this therapeutic area. CBD failed to show any 
detectable metabolic effects despite producing desirable changes in some 
adipokines and gut hormone concentrations. The incidence of AEs was similar 
between treatment groups, and both CBD and THCV were well tolerated. No new 
safety concerns were identified in the study.
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Figure legends
Figure 1. Summary of breakdown of patients enrolled in the study. 125 subjects 
were screened and 62 randomised to this study. 
Figure 2. Compared with placebo, THCV alone caused a significant improvement in 
the concentration of Apo A (P<0.05; A) and adiponectin (P<0.01; B). Data was 
analysed by analysis of covariance and presented as mean ± SEM. CBD caused a 
significant reduction in resistin (P<0.05; C) and an increase in GIP concentration 
(P<0.05; D), when compared with pre-treatment values. Data were analysed post 
hoc using paired t-test and presented as mean ± SEM.
Figure 3. Compared with placebo, THCV alone caused significant improvement in 
fasting glucose (P<0.05; A) and in keeping with this, there was a highly significant 
improvement in β cell function measured by HOMA2 (P<0.01; B). THCV caused 
significant improvement in 3 hour glucose response during OGTT (P<0.05; C), when 
compared with pre-treatment values. 
Data were analysed using 2-way ANOVA and presented as mean ± SEM. (D) 
Compared with pre-treatment values, there was a highly significant improvement in 3 
hour glucose response to OGTT with THCV, when subjects on any oral 
hypoglycaemic therapy other than diet and/or metformin were excluded from 
analysis (P<0.01, n=6). In the same subgroup (analysed post hoc), compared with 
placebo, there was a statistically significant improvement in HbA1c (P<0.05, E). Data 
were analysed post hoc using repeated measures 2 way ANOVA and paired t-test 
respectively and presented as mean ± SEM.
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Table 1. Summary of patient demographics and concomitant therapy.  
CBD 
(n=13)
THCV
(n=12)
1:1 
CBD:THC
V
(n=11)
20:1 
CBD:THC
V
(n=12)
Placeb
o
(n=14)
Total
(n=62)
Male (number of 
subjects and (%))
10 (77) 10 (83) 6 (55) 9 (75) 7 (50) 42 (68)
Female (number of 
subjects and (%))
3 (23) 2 (17) 5 (45) 3 (25) 7 (50) 20 (32)
Age (years, Mean 
(SD))
56.8 
(9.9)
62.5 
(12.6)
59.3 (8.8) 58.0 (8.1) 58.6 
(7.7)
59.0 
(9.4)
Weight (kg, Mean 
(SD))
97.2 
(13.8)
98.3 
(17.5)
100.7 
(14.5)
100.5 
(17.9)
94.2 
(19.1)
98.0 
(16.4)
BMI (kg/m2 Mean 
(SD))
33.2 
(5.4)
34.0 
(6.5)
36.4 (5.6) 35.4 (4.6) 33.4 
(7.0)
34.4(5.8
)
Duration since 
diagnosis of diabetes 
(years, Mean (SD))
2.8 
(3.3)
4.8 
(3.6)
4.4 (2.7) 5.1 (3.3) 3.8 
(3.5)
4.2 (3.3)
Number (%) of patients on anti-diabetic and lipid lowering therapy
Metformin 9 (69) 9 (75) 10 (91) 11 (92) 12 (86) 51 (82)
DPP-4 Inhibitors 1 (8) 1 (8) 1 (9) 1 (8) 1 (7) 5 (8)
Sulfonylureas 3 (23) 5 (42) 4 (36) 3 (25) 4 (29) 19 (31)
Statins 9 (69) 11 (92) 10 (91) 8 (67) 13 (93) 51 (82)
Table 2. Clinical data before (baseline) and after (treatment) 13 weeks of 
randomised treatment
Variable CBD (n=13) THCV (n=12) 1:1 CBD : THCV 
(n=11)
20:1 CBD : 
THCV (n=12)
Placebo (n=14)
Basel
ine
Treatm
ent
Basel
ine
Treatm
ent
Basel
ine
Treatm
ent
Basel
ine
Treatm
ent
Basel
ine
Treatm
ent
HDL-C 
(mmol/l)
1.0 ± 
0.3
1.0 ± 
0.3
1.1 ± 
0.1
1.1 ± 
0.2
1.0 ± 
0.2
1.0 ±  
0.3
1.0 ± 
0.1
1.0 ± 
0.1
1.0 ± 
0.3
1.0 ± 
0.2
Total-C 
(mmol/l)
4.5 ± 
0.9
4.3 ± 
0.7
3.8 ± 
0.9
3.7 ± 
1.0
4.2 ± 
1.1
3.8 ± 
0.7
4.6 ± 
0.9
4.2 ± 
0.6
4.0± 
0.7
3.9 ± 
0.9
LDL-C 
(mmol/l)
2.5 ± 
0.7
2.4 ± 
0.6
2.0 ± 
0.6
2.0 ± 
0.8
2.2 ± 
0.8
2.0 ± 
0.5
2.8 ± 
0.6
2.5 ± 
0.5
2.2 ± 
0.6
2.2 ± 
0.7
HDL:LDL-
C ratio
0.5 ± 
0.2
0.4 ± 
0.2
0.6 ± 
0.3
0.6 ± 
0.3
0.5 ± 
0.2
0.6 ± 
0.2
0.4 ± 
0.1
0.4 ± 
0.1
0.5 ± 
0.1
0.5 ± 
0.1
UC VLDL-
C (mmol/l)
0.8 ± 
0.4
1.0 ± 
0.5
1.0 ± 
0.7
0.9 ± 
0.7
1.0 ± 
0.5
1.0 ± 
0.4
1.1 ± 
0.4
1.0 ± 
0.3
1.0±  
0.5
0.9 ± 
0.4
Triglyceri
des 
(mmol/l)
2.2 ± 
1.4
2.3 ± 
1.3
1.7 ± 
1.1
1.8 ± 
1.5
2.4 ± 
1.6
2.2 ± 
1.2
1.9 ± 
0.7
1.9 ± 
0.7
2.1 ± 
1.4
2.0 ± 
1.1
Apo A 
(μmol/l)
48.6 
± 9.7
43.6 ± 
6.6
48.5 
± 7.0
49.1 ± 
6.4b
48.7 
± 
11.1
46.8 ± 
7.4
48.7 
± 
10.0
45.7 ± 
6.3
47.3 
± 8.8
43.9 ± 
7.2
Apo B 
(μmol/l)
3.1 ± 
0.8
3.3 ± 
0.7
2.6 ± 
0.6
2.7 ± 
1.0
3.0 ± 
0.9
2.9 ± 
0.7
3.4 ± 
0.7
3.4 ± 
0.6
2.9 ± 
0.7
3.0 ± 
0.6
Apo 
B:Apo A 
ratio
0.6 ± 
0.2
0.7 ± 
0.2
0.5 ± 
0.1
0.5 ± 
0.2a
0.6 ± 
0.2
0.6 ± 
0.2
0.7 ± 
0.2
0.7 ± 
0.1
0.6 ± 
0.2
0.7 ± 
0.1
NEFA 
(mmol/l)
0.6 ± 
0.2
0.5 ± 
0.3
0.6 ± 
0.1
0.6 ± 
0.2
0.7 ± 
0.3
0.6 ± 
0.2
0.7 ± 
0.2
0.6 ± 
0.2
0.6 ± 
0.2
0.6 ± 
0.2
Liver TG 
(%)
26.9 
± 
16.9
22.2 ± 
17.1
11.9 
± 8.0
11.5 ± 
13.5
33.3 
± 
18.3
32.2 ± 
26.2
23.2 
± 
14.3
25.4 ± 
17.4
20.5 
± 
15.1
18.5 ± 
15.4
Fasting 
glucose 
(mmol/l)
8.0 ± 
2.3
8.4 ± 
2.8
7.4 ± 
2.3
6.7 ± 
1.9b
8.5 ± 
2.5
8.7 ± 
2.0
8.4 ± 
2.8
8.8 ± 
3.1
7.6 ± 
1.4
8.0 ± 
1.6
Fructosa
mine 
(µmol/l)
259.
5 ± 
34.4
256.8 
± 44.6
238.
2 ± 
25.0
239.3 
± 28.7
254.
4 ± 
35.7
256.0 
± 55.2
253.
3 ± 
34.8
268.8 
± 58.2
241.
4 ± 
19.3
253.7 
± 32.0
HbA1c 
(%)
6.9 ± 
0.9
7.0 ± 
1.1
6.6 ± 
0.6
6.5 ± 
0.7
7.2 ± 
1.1
7.4 ± 
1.5
7.2 ± 
0.9
7.3 ± 
1.3
7.0 ± 
0.7
7.3 ± 
1.0
Glucose - 
2 h OGTT 
(mmol/l)
7.4 ± 
2.4
6.6 ± 
2.7
5.7 ± 
3.1
6.2 ± 
2.7
8.7 ± 
3.8
8.8 ± 
2.5
5.6 ± 
3.4
6.6 ± 
2.3
7.9 ± 
2.6
8.4 ± 
2.2
Insulin - 2 
h OGTT 
(pmol/l)
604.
1 ± 
605.
2
454.8 
± 
387.5
661.
0 ± 
381.
2
724.9 
± 
589.6
789.
5 ± 
677.
2
900.2 
± 
875.8
659.
3 ± 
570.
4
651.6 
± 
730.0
653.
6 ± 
381.
5
619.7 
± 
455.3
Fasting 
insulin 
(pmol/l)
110.
3 ± 
42.8
123.8 
±  
60.8
152.
9 ±  
94.2
203.5 
±  
197.7
175.
3 ± 
86.1
185.7 
± 67.6
197.
6 ± 
107.
9
192.2 
± 69.1
171.
7 ±  
105.
0
179.7 
±  
75.7
C-peptide 
(nmol/l)
0.9 ± 
0.2
0.9 ± 
0.2
1.0 ± 
0.3
1.1 ± 
0.5
1.2 ± 
0.2
1.2 ± 
0.3
1.1 ± 
0.3
1.2 ± 
0.3
1.0 ± 
0.4
1.1 ± 
0.4
HOMA2-
IR
2.3 ± 
0.9
2.6 ± 
1.5
3.0 ± 
1.9
3.8 ± 
3.3
3.5 ± 
1.6
3.7 ± 
1.3
4.2 ± 
2.9
4.0 ± 
1.5
3.4 ± 
2.1
3.6 ± 
1.5
HOMA2 
insulin 
sensitivit
y
51.3 
± 
20.1
53.0 ±  
36.2
47.3 
± 
32.4
53.5 ± 
44.3
34.9 
± 
17.1
30.4 ± 
12.9
30.2 
± 
11.4
28.9 ± 
11.5
42.4 
± 
29.2
37.8 ± 
32.2
HOMA2 B 
cell 
function
70.9 
± 
27.2
69.6 ± 
31.5
105.
1 ± 
64.7
144.4 
± 
110.3
c
95.7 
± 
50.7
93.8 ± 
47.5
103.
7 ± 
60.6
97.9 ± 
50.5
96.4 
± 
41.4
94.7 ± 
39.2
BMI 
(kg/m2)
33.2 
± 5.4
33.0 ± 
4.9
34.0 
± 6.5
33.8 ± 
6.7
36.4 
± 5.6
36.1 ± 
5.7
35.4 
± 4.6
35.4 ± 
4.4
33.4 
± 7.0
32.9 ± 
7.7
Waist 
circumfer
ence (cm)
107.
7 ± 
10.8
108.0 
± 10.6
115.
3 ± 
13.1
114.9 
± 13.8
115.
4 ± 
9.5
116.2 
± 11.8
113.
7 ± 
13.1
113.5 
± 12.1
109.
2 ± 
13.0
108.4 
± 13.1
Waist-to-
hip ratio
1.0 ± 
0.05
1.0 ± 
0.1
1.0 ± 
0.05
1.0 ± 
0.06
1.0 ± 
0.1
1.0 ± 
0.05
1.0 ± 
0.1
1.0 ± 
0.1
1.0 ± 
0.1
1.0 ± 
0.1
Neck 
circumfer
ence (cm)
42.4 
± 3.3
42.1 ± 
3.7
42.8 
± 3.8
42.8 ± 
3.6
42.7 
± 3.3
42.2 ± 
3.8
42.8 
± 3.6
42.5 ± 
4.0
41.7 
± 4.8
41.1 ± 
4.8
Visceral 
abdomina
l fat (l)
8.1 ± 
1.9
8.5 ± 
2.2
9.1 ± 
3.5
9.0 ± 
3.5
8.5 ± 
3.0
8.6 ± 
2.7
9.1 ± 
2.5
10.2 ± 
2.2
7.2 ± 
2.4
7.5 ± 
3.4
Appetite 
0-10 NRS 
score
5.6 ± 
1.0
4.9 ± 
1.0
5.4 ± 
1.7
5.0 ± 
1.5
4.7 ± 
1.2
3.6 ± 
1.6
5.0 ± 
2.2 4.1 ± 1.9
5.1 ± 
1.3
4.5 ± 
1.3
Systolic 
BP 
(mmHg)
133.
4 ± 
16.4
132.2 
± 13.0
135.
9 ± 
13.4
132.8 
± 17.1
126.
4 ± 
11.6
134.3 
± 12.8
132.
7 ± 
11.0
134.2 
± 14.8
137.
2 ± 
11.9
140.4 
± 11.2
Diastolic 
BP 
(mmHg)
70.1 
± 8.8
70.6 ± 
8.8
70.6 
± 
12.2
71.0 ± 
9.4
73.2 
± 6.8
77.5 ± 
7.7
73.5 
± 
10.4
72.2 ± 
10.5
73.0 
± 9.5
72.3 ± 
10.6
Pulse rate 
(bpm)
71.5 
± 
17.7
70.5 ± 
15.7
74.5 
± 
12.3
74.1 ± 
12.4
80.1 
± 
12.2
76.6 ± 
8.0
77.1 
± 
12.1
82.0 ± 
15.8
72.1 
± 
10.8
75.5 ± 
7.3
BDI-II 
score
3.8 ± 
3.5
4.6 ± 
3.7
2.8 ± 
3.8
3.3 ± 
3.3
4.5 ± 
5.2
4.7 ± 
5.0
2.8 ± 
2.7
7.9 ± 
7.6
3.5 ± 
3.9
3.5 ± 
3.2
AEA 0.2 ± 0.1
0.2 ± 
0.05
0.2 ± 
0.1
0.2 ± 
0.1
0.2 ± 
0.1
0.2 ± 
0.1
0.2 ± 
0.04
0.2 ± 
0.1
0.2 ± 
0.1
0.2 ± 
0.1
2-AG 5.0 ± 2.9
4.7 ± 
2.9
4.3 ± 
1.7
13.6 ± 
28.6
6.2 ± 
3.1
5.0 ± 
1.5
3.8 ± 
1.5
3.7 ± 
1.7
5.0 ± 
3.3
5.3 ± 
3.4
OEA 2.4 ± 1.1
1.8 ± 
0.7
2.4 ± 
1.0
2.3 ± 
0.6
2.5 ± 
0.8
2.2 ± 
0.7
2.2 ± 
0.5
2.2 ± 
0.8
2.4 ± 
0.5
2.1 ± 
0.5
PEA 2.7 ± 1.9
1.8 ± 
0.7
2.7 ± 
1.1
2.5 ± 
0.7
2.5 ± 
0.7
2.4 ± 
0.6
2.5 ± 
1.2
2.6 ± 
1.7
2.9 ± 
1.3
2.0 ± 
0.4
Data are mean ± SD; aP<0.05, bP<0.01 compared with placebo; Abbreviations: AEA, 
N-arachidonoylethanolamine; Apo, Apolipoprotein; BDI-II, Beck Depression 
Inventory-II; BMI, Body mass index; BP, blood pressure; HbA1c, glycosylated 
haemoglobin A1c; HDL, high density lipoprotein;  HOMA2-IR, homeostatic 
assessment model 2 - insulin resistance; LDL-C, low density lipoprotein cholesterol; 
NEFA, non-esterified fatty acid; OEA, oleoylethanolamine; OGTT, oral glucose 
tolerance test; PEA, palmitoylethanolamine; TG; triglyceride, UC, ultracentrifugation; 
VLDL, very low density lipoprotein; 2-AG, 2-arachidonoylglycerol 


